

**2025**  
**Prior Authorization Criteria**  
**For**  
**Non-Grandfathered Commercial**  
**Plans**

**Drugs**  
**Verzenio**

**Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria**

**Required Medical Information**

Diagnosis Metastatic ER+ HER- Breast cancer.

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

Hematologist/Oncologist

**Coverage Duration**

Up to 12 months or until disease progression or toxicity

**Other Criteria**

Verzenio is a CDK 4/6 inhibitor indicated for first-line/second line treatment of metastatic ER+/HER- breast cancer used in combination with an aromatase inhibitor or fulvestrant. Also indicated for node positive HER2-/HR+ early stage breast cancer at high risk of recurrence. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **abiraterone (Zytiga)**

---

### **Drugs**

Abiraterone Acetate Oral Tablet 250 MG

### **Covered Uses**

FDA approved indications

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

### **Other Criteria**

Abiraterone is indicated to treat metastatic prostate cancer. It is taken orally along with prednisone daily. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**

**Hadlima, Hadlima PushTouch**

**Covered Uses**

All FDA-approved indications not otherwise excluded from Part D. Adalimumab is indicated for the treatment of confirmed rheumatoid arthritis (RA), plaque psoriasis (PP), Psoriatic Arthritis (PSA) Crohn's disease (CD), ulcerative colitis (UC), Hydradenitis suppurativa, uveitis. This is non-preferred for commercial, ACA, and Exchange. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Must be written by Rheumatology, Dermatology or Specialist trained in management of prescribed condition. Dosing for indication is the FDA approved dose, off label dosing for an indication is not covered. For RA Patient must fail adequate trial of MTX in combination with a DMARD If MTX contraindicated, must try combination of 2-nonbiologic DMARDS (3 month trial in past 6 months). For Ankylosing Spondylitis PT must fail MTX or sulfasalazine and 2 NSAIDS within past 6 months. For Plaque Psoriasis patient must fail MTX or Soriatane and topical therapy. For Psoriatic Arthritis Patient must fail adequate trial of MTX or LEF in past 6 months. Renflexis, Azathioprine, and 6 Mercaptopurine. For hidradenitis suppurativa must have moderate to severe disease and have failed recent trial 8 to 12 week trial in past month of oral clindamycin and rifampin or doxycycline/Minocycline, Infliximab, AND oral retinoid (acitretin or isotretinoin) unless contraindicated in the past 6 months. For Uveitis patient must fail 8-12 week trial of methotrexate

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

**Prescriber Restriction**

Must be written by Rheumatology, Dermatology or Specialist trained in management of prescribed condition.

**Coverage Duration**

12 months

**Other Criteria**

**Drugs**  
**Gilotrif**

**Covered Uses**

Patient must have NSCLC mutations consistent with FDA label. Test for T790M mutation if previously on a TKI inhibitor

**Exclusion Criteria**

**Required Medical Information**

Medical notes, previous treatment history and associated studies, including test for T790M mutation if previously on a TKI inhibitor

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

Prescribing restricted to oncology.

**Coverage Duration**

Up to 12 months or until disease progression or toxicity

**Other Criteria**

Gilotrif is an oral tyrosine kinase inhibitor indicated to treat NCSLC with the genetic tumor markers of exon 19 deletion and exon 21 substitution. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **alectinib (Alecensa)**

---

### **Drugs Alecensa**

#### **Covered Uses**

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater

#### **Exclusion Criteria**

#### **Required Medical Information**

##### **Age Restriction**

Ages approved in FDA labeling/compendia

##### **Prescriber Restriction**

Prescriber must be an oncologist

##### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

##### **Other Criteria**

Alecensa is indicated to treat patients with ALK+ metastatic Non-Small cell lung cancer. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician

## alitretinoin (Panretin)

---

### **Drugs** **Panretin**

#### **Covered Uses**

FDA approved indications. Failure of vinblastine.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

#### **Coverage Duration**

12 months

#### **Other Criteria**

Panretin is a retinoid indicated for Kaposi sarcoma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**

Ambrisentan

**Covered Uses**

FDA approved indications. Pulmonary hypertension must be diagnosed by heart catheterization. Patient must have failed or have contraindication to sildenafil. Evaluation, EKG, diffusion studies, catheterization results and an objective test of exercise ability (6 minute walk) must be submitted with referral. Approved referrals will initially provide coverage for 12 weeks. Continuation of coverage will be determined by an improvement of an objective test of exercise (6 minute walk) from baseline. Follow-up documentation must be submitted for continuation of coverage. Patients who have had an initial positive response based the 12 week follow-up will be approved for an additional 6 months, and re-evaluation with documentation will be required every 6 months for continuation of coverage.

**Exclusion Criteria**

This medication is contraindicated in pregnancy, those of childbearing ability who are not using contraception.

**Required Medical Information**

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

**Coverage Duration**

Initial approval for 12 weeks. See "Covered Use" for continuation of coverage details.

**Other Criteria**

Letairis is an endothelin receptor antagonist used to treat WHO group 1 pulmonary arterial hypertension. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



**Drugs**

**Kineret Subcutaneous Solution Prefilled Syringe**

**Covered Uses**

FDA approved indications. Patient must fail two anti-TNF biologics and Xeljanz.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

**Coverage Duration**

Up to 12 months

**Other Criteria**

Kineret is a biologic agent indicated for treatment of rheumatoid arthritis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## apalutamide (Erleada)

---

### **Drugs** **Erleada**

#### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D. Patient has contraindication to abiraterone or is intolerant for overlapping indications, diabetes is not a contraindication to abiraterone, unless demonstrated trial worsens control.

#### **Exclusion Criteria**

#### **Required Medical Information**

##### **Age Restriction**

Ages approved in FDA labeling/compendia

##### **Prescriber Restriction**

Hematologist / Oncologist

##### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

##### **Other Criteria**

Erleada is indicated for treatment of metastatic castrate sensitive prostate cancer, and non-metastatic castrate resistant prostate cancer. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **aprepitant (Emend)**

---

### **Drugs**

Aprepitant Oral Capsule, **Emend Oral Suspension Reconstituted**

### **Covered Uses**

FDA approved indications. Patient must have failed Zofran. A pre-packaged three-day course of this medication will be approved per each co-pay incidental to a chemotherapy treatment cycle.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Medication will be approved through referrals when written by Oncology

#### **Coverage Duration**

12 months

### **Other Criteria**

Emend is used as part of a three day regimen for chemotherapy induced nausea and vomiting (CINV) of moderate to highly emetogenic Chemotherapy treatments, and Post-Operative Nausea and Vomiting. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **aripiprazole (Abilify)**

---

### **Drugs**

**Abilify Maintena Intramuscular Prefilled Syringe**

### **Covered Uses**

FDA approved indications. Failure of oral aripiprazole and lurasidone.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

Approved when written/ordered by a Psychiatrist or Neurologist through referrals for new starts.

### **Coverage Duration**

12 months

### **Other Criteria**

Aripiprazole is a psychotropic medication. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

**Drugs**  
**Strensiq**

**Covered Uses**

All FDA-approved indications not otherwise excluded from Part D. Criteria for coverage as follows: Must meet ALL of the following criteria: 1. Member is diagnosed with any of the following: a. Perinatal/infantile-onset hypophosphatasia (HPP) b. Juvenile-onset hypophosphatasia (HPP) AND 2. Member's diagnosis of HPP is confirmed by or in consultation with an endocrinologist or a bone and mineral specialist. AND 3. Member has skeletal abnormalities indicative of HPP - documentation from the medical record must be provided. a. Note: Examples of skeletal abnormalities include chest wall deformities, hypomineralized skeleton, rickets, nonhealing fractures. AND 4. Member has an alkaline phosphatase (ALP) level below age-adjusted lower limit of normal, while off medications which can lower ALP such as anti-resorptives. AND 5. Member has a pyridoxal-5'-phosphate (PLP) level greater than two times laboratory's upper limit, while off vitamin supplementation (2 week washout) AND 6. Member has an ALPL genetic mutation - laboratory documentation must be provided. AND 7. Member has an onset of clinical signs and symptoms of HPP prior to 12 years of age - documentation from the medical record must be provided. STRENSIQ continued.. AND 8. Strensiq is prescribed by or in consultation with an endocrinologist or a bone and minerals specialist. AND 9. Dose does not exceed 6 mg/kg/week. Initial approval 6 months. Continuation of Strensiq meets definition of Medical Necessity for members when the following criteria are met: 1. Member has demonstrated an objective clinical improvement in symptoms following initiation of asfotase alfa - documentation from the medical record must be provided. This could include improvement in fracture healing, improved 6 minute walk time, improved bone density, reduction in baseline disability. AND 2. Strensiq is prescribed by or in consultation with an endocrinologist or a bone and mineral specialist 3. Dose does not exceed: a. Perinatal/infantile-onset HPP: 9 mg/kg/week b. Juvenile-onset HPP: 6 mg/kg/week

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

**Prescriber Restriction**

**Coverage Duration**

12 months

**Other Criteria**

Strensiq is an enzyme replacement therapy indicated for infantile or pediatric onset hypophosphatasia. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## axitinib (Inlyta)

---

### **Drugs** **Inlyta**

#### **Covered Uses**

Inlyta is an oral tyrosine kinase inhibitor indicated for advanced renal cell carcinoma.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Prescribing restricted to oncology.

#### **Coverage Duration**

12 months

#### **Other Criteria**

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **Benefix**

---

### **Drugs**

#### **Benefix Intravenous Kit**

### **Covered Uses**

Approval will be based on Diagnosis of Hemophilia B and history of Bleeding or joint effusions OR perioperative prophylaxis

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

**Drugs**

Bosentan

**Covered Uses**

FDA approved indications. Pulmonary hypertension must be diagnosed by heart catheterization. Patient must have failed or have contraindication to sildenafil, ambrisentan, and tadalafil. Evaluation, EKG, diffusion studies, catheterization results and an objective test of exercise ability (6 minute walk) must be submitted with referral. Approved referrals will initially provide coverage for 12 weeks. Continuation of coverage will be determined by an improvement of an objective test of exercise (6 minute walk) from baseline. Follow-up documentation must be submitted for continuation of coverage. Patients who have had an initial positive response based the 12 week follow-up will be approved for an additional 6 months, and re-evaluation with documentation will be required every 6 months for continuation of coverage.

**Exclusion Criteria**

This medication is contraindicated in pregnancy, those of childbearing ability who are not using contraception, those on glyburide or cyclosporine and in those with active liver disease.

**Required Medical Information**

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

**Coverage Duration**

Initial approval for 12 weeks. See "Covered Use" for continuation of coverage details.

**Other Criteria**

Tracleer is indicated for the treatment of Primary pulmonary arterial hypertension or pulmonary hypertension related to connective tissue disease. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



## **bosutinib (Bosulif)**

---

### **Drugs**

#### **Bosulif Oral Tablet**

### **Covered Uses**

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. AND Failure of dasatinib.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Restricted to hematology/oncology

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

### **Other Criteria**

Bosulif is indicated for treatment of Ph+ CML after failure of a first line tyrosine kinase inhibitor. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

## C1 esterase inhibitor (Berinert)

---

### Drugs

#### Berinert

### Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

### Exclusion Criteria

Must not be taking medications that can exacerbate the frequency and/or severity of hereditary angioedema (HAE) attacks including estrogens and ACE inhibitors.

### Required Medical Information

Must have C1INH deficiency demonstrated by labs (C1INH and C4 labs)

### Age Restriction

### Prescriber Restriction

Must be prescribed by an immunologist, allergist or hematologist

### Coverage Duration

12 months

### Other Criteria

BERINERT is a plasma-derived C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adult and pediatric patients. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **cabozantinib (Cometriq)**

---

### **Drugs**

**Cometriq (100 MG Daily Dose) Oral Kit 80 & 20 MG, Cometriq (140 MG Daily Dose) Oral Kit 3 x 20 MG & 80 MG, Cometriq (60 MG Daily Dose)**

### **Covered Uses**

FDA approved indications.

### **Exclusion Criteria**

Combination use with other tyrosine kinase inhibitors is excluded.

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Prescriber must be a Hematologist/Oncologist.

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

#### **Other Criteria**

Cometriq is indicated for treatment of metastatic medullary thyroid cancer Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## ceritinib (Zykadia)

---

### **Drugs**

#### **Zykadia Oral Tablet**

### **Covered Uses**

FDA approved indications. Must have progressed on Xalkori.

### **Exclusion Criteria**

Not covered in combination with other tyrosine kinase inhibitors or EGFR inhibitors.

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Must be written by oncologist.

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

### **Other Criteria**

Zykadia is a TKI inhibitor indicated for metastatic NSCLC which is ALK (anaplastic lymphoma kinase) positive, it is indicated for patients who have failed/progressed on crizotinib (Xalkori) Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## cinacalcet hydrochloride (Sensipar)

---

### Drugs

Cinacalcet HCl

### Covered Uses

FDA approved indications. Patient is identified as having hypercalcemia associated with parathyroid carcinoma OR Patient is identified as having hyperparathyroidism secondary ESRD in patient with elevated PTH. Patient must have failed phosphate binders and active Vitamin-D therapy, iPTH must be >300 in dialysis patients. This information is sent to the Referrals Department.

### Exclusion Criteria

Not for use in children, pregnancy, seizure disorder.

### Required Medical Information

#### Age Restriction

Ages approved in FDA labeling/compendia

#### Prescriber Restriction

This medication must be prescribed by Nephrology or Endocrinology or Oncology

#### Coverage Duration

12 months

#### Other Criteria

Sensipar is indicated to treat hyperparathyroidism that is secondary to renal insufficiency or hypercalcemia secondary to parathyroid carcinoma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **clobazam (Onfi)**

---

### **Drugs**

Clobazam Oral Suspension 2.5 MG/ML, Clobazam Oral Tablet

### **Covered Uses**

FDA approved indications. Failure of levetiracetam, topiramate ,and clonazepam.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Approved when written/ordered by a Neurologist through referrals for new starts.

#### **Coverage Duration**

12 Months

#### **Other Criteria**

Onfi is a benzodiazepine indicated to treat seizures. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**  
**Cotellic**

**Covered Uses**

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. Must be prescribed by Oncologist. Must be used in combination with Zelboraf.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

Must be prescribed by Oncologist.

**Coverage Duration**

Up to 12 months or until disease progression or toxicity

**Other Criteria**

Cotellic is indicated for treatment of BRAF+ metastatic or unresectable melanoma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## crizotinib (Xalkori)

---

### **Drugs**

#### **Xalkori Oral Capsule**

### **Covered Uses**

FDA approved indications.

### **Exclusion Criteria**

Not covered in combination with other tyrosine kinase inhibitors or EGFR inhibitors.

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Must be written by oncologist.

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

#### **Other Criteria**

Xalkori is a TKI inhibitor for metastatic NSCLC which is ALK (anaplastic lymphoma kinase) positive, or ROS positive. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



## **dabrafenib (Tafinlar)**

---

### **Drugs**

#### **Tafinlar Oral Capsule**

### **Covered Uses**

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. Patient must have BRAF V600E/K mutation

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Must be written by an oncologist.

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

### **Other Criteria**

Tafinlar is a BRAF inhibitor indicated to treat BRAF+ V600e/k mutation Stage IIIc-IV metastatic Melanoma and NSCLC. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **dalfampridine (Ampyra)**

---

### **Drugs**

Dalfampridine ER

### **Covered Uses**

Diagnosis of multiple sclerosis AND patient is ambulatory.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

### **Coverage Duration**

Initial - 3 months. Renewal - 12 months.

### **Other Criteria**

Ampyra is indicated to treat patients with multiple sclerosis who have walking disability. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## darolutamide (Nubeqa)

---

### **Drugs** **Nubeqa**

#### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D. Patient has contraindication to abiraterone or is intolerant for overlapping indications, diabetes is not a contraindication to abiraterone, unless demonstrated results in poorly controlled diabetes.

#### **Exclusion Criteria**

#### **Required Medical Information**

##### **Age Restriction**

Ages approved in FDA labeling/compendia

##### **Prescriber Restriction**

Hematologist/Oncologist

##### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

##### **Other Criteria**

Nubeqa is indicated for treatment of metastatic castrate sensitive prostate cancer, and non-metastatic castrate resistant prostate cancer. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## dasatinib (Sprycel)

---

### **Drugs**

Dasatinib

### **Covered Uses**

FDA approved indications AND failure of imatinib.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

#### **Other Criteria**

Sprycel is an oral antineoplastic agent used to treat Philadelphia Chromosome + CML and PH+ ALL. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## deferasirox (Exjade)

---

### **Drugs**

Deferasirox Oral Tablet Soluble

### **Covered Uses**

FDA approved indications Patient has failed or is intolerant to Deferoxamine.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

Exjade is an oral medication used to treat iron overload typically in patients receiving chronic RBC transfusions. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## degarelix (Firmagon)

---

### **Drugs** **Firmagon**

#### **Covered Uses**

FDA approved indications. Limited to two per month.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Written by oncology or urology

#### **Coverage Duration**

12 months

#### **Other Criteria**

Firmagon is indicated to treat advanced prostate cancer. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**

**Prolia Subcutaneous Solution Prefilled Syringe**

**Covered Uses**

FDA approved indications Intolerance or contraindication to injectable bisphosphonate required for coverage of Prolia.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

**Coverage Duration**

12 months

**Other Criteria**

Prolia is a RANK-L ligand antagonist indicated for treatment of osteoporosis and prevention of osteoporosis for patients taking aromatase inhibitors. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **dextromethorphan / quinidine (Nuedexta)**

---

### **Drugs**

#### **Nuedexta**

### **Covered Uses**

FDA approved indications.

### **Exclusion Criteria**

Not covered for off-label use

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Prescriber must be a neurologist.

#### **Coverage Duration**

Up to 12 months

#### **Other Criteria**

Nuedexta is indicated to treat pseudobulbar affect. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



## **dimethyl fumarate (Tecfidera)**

---

### **Drugs**

Dimethyl Fumarate Oral, Dimethyl Fumarate Starter Pack Oral

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D. All FDA-approved indications

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

Neurology

### **Coverage Duration**

12 months

### **Other Criteria**

Dimethyl fumarate is an oral CMT (disease modifying treatment) indicated to treat relapsing remitting multiple sclerosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **dornase alfa (Pulmozyme)**

---

### **Drugs**

**Pulmozyme Inhalation Solution 2.5 MG/2.5ML**

### **Covered Uses**

FDA approved indications. Patient must have an FVC  $\geq$  40% of predicted value and recurrent pulmonary infections.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Must be written by a pulmonologist.

#### **Coverage Duration**

Up to 12 months

#### **Other Criteria**

Pulmozyme is indicated to reduce pulmonary exacerbation in patients with cystic fibrosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **dronedarone (Multaq)**

---

### **Drugs Multaq**

#### **Covered Uses**

FDA approved indications. Must have previously failed or have contraindication to both sotalol and amiodarone.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

#### **Coverage Duration**

12 months

#### **Other Criteria**

Multaq is indicated for treatment of atrial fibrillation. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**  
**Orilissa**

**Covered Uses**

All FDA-approved indications not otherwise excluded from Part D. Orilissa is indicated for moderate to severe pain due to endometriosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Criteria for coverage as follows: FDA approved indications. Failure of an NSAID and oral contraceptive/progestin for endometriosis.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

**Prescriber Restriction**

OB/GYN

**Coverage Duration**

6 months

**Other Criteria**

**Drugs**  
**OriaHnn**

**Covered Uses**

All FDA-approved indications not otherwise excluded from Part D. OriaHnn is indicated for treatment of heavy menstrual bleeding due to uterine fibroids. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Criteria for coverage as follows: FDA approved indications. Failure of an NSAID and oral contraceptive/progestin for endometriosis.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

**Prescriber Restriction**  
OB/GYN

**Coverage Duration**  
24 months

**Other Criteria**

## **eltrombopag (Promacta)**

---

### **Drugs**

**Promacta Oral Packet 12.5 MG, Promacta Oral Tablet**

### **Covered Uses**

FDA approved indications. Patient must have chronic ITP and bleed risk, with platelet count less than 30,000, and refractory to IVIG, corticosteroids or splenectomy.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

#### **Coverage Duration**

Up to 12 months

#### **Other Criteria**

Promacta is indicated to treat ITP and thrombocytopenia secondary to HCV treatment. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## enasidenib (Idhifa)

---

### **Drugs** **Idhifa**

#### **Covered Uses**

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater.

#### **Exclusion Criteria**

#### **Required Medical Information**

##### **Age Restriction**

Ages approved in FDA labeling/compendia

##### **Prescriber Restriction**

Prescriber must be a Hematologist/Oncologist

##### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

##### **Other Criteria**

Idhifa is indicated for treatment of relapsed or refractory AML in patients with an IDH2 mutation as detected by an approved test Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## entrectinib (Rozlytrek)

---

### **Drugs**

#### **Rozlytrek Oral Capsule**

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

Rozlytrek is a kinase inhibitor indicated for solid tumors with NTRK-Fusions and ROS-1 mutated Non-Small Cell lung cancer. Medical history, studies, and appropriate confirmatory tests are reviewed in Referrals and if approved will notify pharmacy and the physician.



**Drugs**  
**Xtandi**

**Covered Uses**

Criteria for coverage as follows: •FDA approved indications •Covered for 6 months and continuation based on lack of disease progression. •Coverage will be based on failure of Abiraterone for overlapping indications (Metastatic Prostate Cancer and Castrate sensitive high risk non-metastatic cancer). Diabetes is not considered a contraindication unless a demonstrated trial of abiraterone results in poorly controlled diabetes. •Must be prescribed by oncologist or urologist.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

Must be prescribed by oncologist or urologist.

**Coverage Duration**

Covered for 6 months and continuation based on lack of disease progression.

**Other Criteria**

Xtandi is an androgen receptor blocker used for Castrate Resistant Prostate Cancer pre- and post-chemotherapy. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **epoetin alpha-epbx (Retacrit)**

---

### **Drugs**

**Retacrit Injection Solution 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML**

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D. Pharmacy coverage criteria as follows: FDA approved indications. Patient must have adequate iron stores (ferritin greater than or equal to 100 ng/ml, transferrin saturation greater than 20%). Hemoglobin for initiation and maintenance must be compliant with current FDA labeling.

### **Exclusion Criteria**

ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.

### **Required Medical Information**

#### **Age Restriction**

#### **Prescriber Restriction**

#### **Coverage Duration**

6 months

### **Other Criteria**

ESAs are used to treat anemia related to Chronic Kidney Disease, Chemotherapy, Myelodysplastic Syndrome, Antiviral therapy. Prior authorization is required for pharmacy coverage of medication. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

**Drugs**  
**Aimovig**

**Covered Uses**

Aimovig is a anti-CGRP antibody indicated for prophylaxis of Episodic and Chronic Migraines

**Episodic Migraines**Aimovig will be approved based upon all of the following criteria:(1) Diagnosis of episodic migraines with both of the following:(a) Less than 15 headache days per month(b) Patient has 4 to 14 migraine days per month-AND-(2) Recent trial and failure (trial of at least three months) of two generic medications FDA indicated for migraine prophylaxis (topiramate/divalproex). If either or both are contraindicated or not tolerated the medications below could be used:(a) Amitriptyline (b) atenolol, metoprolol, nadolol, propranolol, or timolol(e) Venlafaxine (Effexor/Effexor XR)AND (3) Medication will not be used in combination with an oral CGRP antagonist or inhibitorAuthorization will be issued for 6 months.

**2. Reauthorization.** Aimovig will be approved based on all of the following criteria:(1) Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity-AND-(2) Medication will not be used in combination with an oral CGRP Antagonist.Authorization will be issued for 12 months.

**B. Chronic Migraines**

**1. Initial Therapy**Aimovig will be approved based upon all of the following criteria:(1) Diagnosis of chronic migraines with both of the following:(a) Greater than or equal to 15 headache days per month continued.(b) Greater than or equal to 8 migraine days per month-AND-Recent trial and failure (trial of at least three months) of two generic medications FDA indicated for migraine prophylaxis (topiramate/divalproex). If either or both are contraindicated or not tolerated the medications below could be used:(a) Amitriptyline (b) atenolol, metoprolol, nadolol, propranolol, or timolol(e) Venlafaxine (Effexor/Effexor XR)-AND-(3) Medication will not be used in combination with an oral CGRP antagonist Authorization will be issued for 6 months.

**2. Reauthorization.** Aimovig will be approved based on all of the following criteria:(1) Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity-AND-(2) Medication will not be used in combination with an oral CGRP Antagonist.Authorization will be issued for 12 months.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

**Prescriber Restriction**

**Coverage Duration**

6 to 12 months

**Other Criteria**

## erlotinib (Tarceva)

---

### **Drugs**

Erlotinib HCl

### **Covered Uses**

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

Tarceva is indicated to treat patients with metastatic non-small cell lung cancer who possess an EGFR mutation. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## eslicarbazepine (Aptiom)

---

### **Drugs** **Aptiom**

#### **Covered Uses**

FDA approved indications. Failure of Oxcarbazepine and carbamazepine.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Must be written by neurology for adjunctive treatment of seizures.

#### **Coverage Duration**

12 months

#### **Other Criteria**

Aptiom is an anti-convulsant indicated for adjunctive treatment of partial seizures. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

## **estrogens, esterified (USP) (Menest)**

---

### **Drugs**

**Menest Oral Tablet 0.3 MG, 0.625 MG, 1.25 MG**

### **Covered Uses**

Used for palliative treatment of breast cancer.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Must be written by an oncologist.

#### **Coverage Duration**

Up to 12 months

#### **Other Criteria**

Menest is only covered for palliative treatment of breast cancer. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**

**Enbrel Mini, Enbrel Subcutaneous Solution 25 MG/0.5ML, Enbrel Subcutaneous Solution Prefilled Syringe, Enbrel Subcutaneous Solution Reconstituted, Enbrel SureClick Subcutaneous Solution Auto-Injector**

**Covered Uses**

Indicated for RA, JRA, PSA, and Plaque Psoriasis. See "Guidelines for Enbrel" form.

**Exclusion Criteria**

FDA labeled contraindications

**Required Medical Information**

Medical notes, previous treatment history and associated studies

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

Rheumatology, Dermatology or Specialist trained in management of prescribed condition

**Coverage Duration**

Up to 12 months

**Other Criteria**

For RA Patient must fail Hadlima and Renflexis. For Ankylosing Spondylitis must fail Hadlima and Renflexis. For Plaque Psoriasis patient must fail Hadlima, and biosimilar ustekinumab. For Psoriatic Arthritis Patient must fail adequate trial of Hadlima and biosimilar Ustekinumab.

## everolimus (Afinitor)

---

### **Drugs**

Everolimus Oral Tablet

### **Covered Uses**

Afinitor is an oral tyrosine kinase inhibitor indicated to treat several malignancies.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Prescribing restricted to oncology.

#### **Coverage Duration**

12 months

#### **Other Criteria**

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



## everolimus (Zortress)

---

### **Drugs**

Everolimus Oral Tablet

### **Covered Uses**

FDA approved indications. Patient must have failure or intolerance to a calcineurin inhibitor.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Prescriber must be a transplant specialist.

#### **Coverage Duration**

12 months

#### **Other Criteria**

Zortress is an immunosuppressive anti-rejection agent for solid organ transplant. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **fentanyl citrate lozenge (Actiq)**

---

### **Drugs**

fentaNYL Citrate Buccal Lozenge On A Handle

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D. Fentanyl citrate lozenges approved after failure of hydromorphone IR and morphine IR and oxycodone IR

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Approved when written/ordered by an Oncologist or Pain Management through referrals.

#### **Coverage Duration**

12 months

#### **Other Criteria**

Fentanyl Citrate Lozenge is a short acting opioid indicated for cancer breakthrough pain. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **fentanyl transdermal product (Duragesic)**

---

### **Drugs**

Fentanyl Transdermal Patch 72 Hour 100 MCG/HR, 12 MCG/HR, 25 MCG/HR, 50 MCG/HR, 75 MCG/HR

### **Covered Uses**

FDA approved indications.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Approved when written/ordered by an Oncologist or Pain Management through referrals.

#### **Coverage Duration**

12 months

#### **Other Criteria**

Fentanyl patch is a long acting opioid analgesic indicated for moderate to severe chronic pain. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **fingolimod (Gilenya)**

---

### **Drugs**

Fingolimod HCl

### **Covered Uses**

Covered for patients who have failed a trial of glatiramer and Dimethyl Fumerate

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Must be written by a neurologist

#### **Coverage Duration**

12 months

#### **Other Criteria**

Gilenya is an oral medication indicated for treatment of relapsing remitting multiple sclerosis Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## Drugs

### Emgality, Emgality (300 MG Dose)

#### Covered Uses

All FDA-approved indications not otherwise excluded from Part D. Emgality is an anti-CGRP antibody indicated for prophylaxis of Episodic and Chronic Migraines, and Cluster Headaches. Episodic Migraines: Emgality 120 mg will be approved based upon all of the following criteria: (1) Diagnosis of episodic migraines with both of the following: (a) Less than 15 headache days per month (b) Patient has 4 to 14 migraine days per month -AND- (2) Recent trial and failure (trial of at least three months) of two generic medications FDA indicated for migraine prophylaxis (topiramate/divalproex). If either or both are contraindicated or not tolerated the medications below could be used: (a) Amitriptyline (b) atenolol, metoprolol, nadolol, propranolol, or timolol (e) Venlafaxine (Effexor/Effexor XR) -AND- (3) Medication will not be used in combination with an oral CGRP antagonist or inhibitor. Authorization will be issued for 6 months. B. Chronic Migraines 1. Initial Therapy: Emgality 120 mg will be approved based upon all of the following criteria: (1) Diagnosis of chronic migraines with both of the following: (a) Greater than or equal to 15 headache days per month Continued. (b) Greater than or equal to 8 migraine days per month -AND- Recent trial and failure (trial of at least three months) of two generic medications FDA indicated for migraine prophylaxis (topiramate/divalproex). If either or both are contraindicated or not tolerated the medications below could be used: (a) Amitriptyline (b) atenolol, metoprolol, nadolol, propranolol, or timolol (e) Venlafaxine (Effexor/Effexor XR) -AND- (3) Medication will not be used in combination with an oral CGRP antagonist. Authorization will be issued for 6 months. C. Episodic Cluster Headache 1. Initial Therapy: a. Emgality 100 mg will be approved based upon all of the following criteria: (1) Diagnosis of episodic cluster headache -AND- (2) Patient has experienced at least 2 cluster periods lasting from 7 days to 365 days, separated by pain-free periods lasting at least three months. -AND- (3) Medication will not be used in combination with an oral CGRP antagonist. -AND- (4) Patient failed topiramate and diltiazem. Authorization will be issued for 6 months.

#### Exclusion Criteria

#### Required Medical Information

#### Age Restriction

#### Prescriber Restriction

consultation with NEUROLOGY

#### Coverage Duration

See covered uses

#### Other Criteria

## gefitinib (Iressa)

---

### **Drugs**

Gefitinib

### **Covered Uses**

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. T790 mutation testing when indicated i.e. previously treated with a TKI inhibitor

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

Must be prescribed by Oncologist

### **Coverage Duration**

12 Months

### **Other Criteria**

Iressa is indicated to treat non-small cell lung cancer with EGFR mutation exon 19 deletion or Exon 21 substitution mutations. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## glucagon (Baqsimi) nasal powder

---

### **Drugs**

#### **Baqsimi One Pack**

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

Ordered by an endocrinologist.

### **Coverage Duration**

12 months

### **Other Criteria**

Baqsimi is indicated for severe hypoglycemia where patient is unable to eat, drink or follow commands.

Baqsimi is intranasal but does not need to be inhaled, patient does not need to be conscious for Baqsimi to be administered. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

Limit of 1 device per dispensing, two per year.

## Hepatitis C Direct Acting Antivirals (DAA)

---

### Drugs

**Mavyret Oral Tablet, Zepatier**

### Covered Uses

FDA approved indications. Mavyret is the preferred DAA for all genotypes, other DAAs will be covered on a case by case basis if Mavyret use is not supported by current FDA indication or HCV guidelines based on patient specific characteristics.

### Exclusion Criteria

### Required Medical Information

#### Age Restriction

Ages approved in FDA labeling/compendia

#### Prescriber Restriction

Gastroenterologist or Infectious Disease

### Coverage Duration

12 months

### Other Criteria

Mavyret is the exclusive and preferred DAA for treatment of HCV in chronically infected non-cirrhotic and compensated cirrhotic patients for genotypes 1-6. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



## Humulin U-500

---

### Drugs

**Humulin R U-500 (Concentrated), Humulin R U-500 KwikPen Subcutaneous Solution Pen-Injector**

### Covered Uses

Initiation restricted to endocrinology. Insulin requirements of >200 units/day.

### Exclusion Criteria

### Required Medical Information

### Age Restriction

Ages approved in FDA labeling/compendia

### Prescriber Restriction

Initiation restricted to endocrinology.

### Coverage Duration

12 months

### Other Criteria

Humulin U 500 is used to treat insulin resistant diabetes mellitus. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **ibrutinib (Imbruvica)**

---

### **Drugs**

**Imbruvica Oral Capsule, Imbruvica Oral Tablet 420 MG, 560 MG**

### **Covered Uses**

FDA approved indications. NCCN supported use with evidence rating 2a or greater.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Must be prescribed by Hematologist/oncologist.

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

#### **Other Criteria**

Imbruvica is a BTK inhibitor used to treat B cell lymphomas. It is indicated for relapsed waldenstroms macroglobinemia, refractory chronic lymphocytic leukemia and Mantle Cell Lymphoma, and first line CLL. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **ibrutiniv (Imbruvica Sln)**

---

### **Drugs**

#### **Imbruvica Oral Suspension**

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

Hematology/ Oncology/ Transplant Specialist

### **Coverage Duration**

12 months

### **Other Criteria**

Unable to swallow or use a tablet or capsule

## idelalisib (Zydelig)

---

### **Drugs** **Zydelig**

#### **Covered Uses**

FDA approved indications.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Must be written by oncologist.

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

#### **Other Criteria**

Zydelig is a PI3K kinase inhibitor for treatment of relapsed Chronic lymphocytic leukemia, relapsed follicular lymphoma, and small lymphocytic lymphoma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## iloperidone (Fanapt)

---

### **Drugs**

**Fanapt, Fanapt Titration Pack**

### **Covered Uses**

FDA approved indications. Failure of aripiprazole, lurasidone.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

Fanapt is indicated to treat schizophrenia. Prior authorization only applies to existing members who are new starts on the drug. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**  
**Xeomin**

**Covered Uses**

FHCP covers this medication only for medically necessary purposes, like cervical dystonia, not responsive to physical therapy, blepharospasm that interferes significantly with vision, and headache not responsive to preventive and acute therapy by Neurology for at least 16 weeks.

**Exclusion Criteria**

FDA labeled contraindications OR cosmetic conditions

**Required Medical Information**

Medical notes, previous treatment history and associated studies

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

**Coverage Duration**

12 months

**Other Criteria**

## interferon beta-1a (Avonex)

---

### **Drugs**

**Avonex Pen Intramuscular Auto-Injector Kit, Avonex Prefilled Intramuscular Prefilled Syringe Kit**

### **Covered Uses**

Failure of glatiramer and Dimethyl Fumerate for new starts.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

Avonex is an interferon indicated to treat multiple sclerosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## interferon beta-1a (Rebif)

---

### **Drugs**

**Rebif Rebidose Subcutaneous Solution Auto-Injector, Rebif Rebidose Titration Pack Subcutaneous Solution Auto-Injector, Rebif Subcutaneous Solution Prefilled Syringe, Rebif Titration Pack Subcutaneous Solution Prefilled Syringe**

### **Covered Uses**

Failure of glatiramer and Dimethyl Fumerate for new starts.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

#### **Coverage Duration**

12 months

#### **Other Criteria**

Rebif is an interferon indicated to treat multiple sclerosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



## interferon beta-1b (Betaseron)

---

### **Drugs**

#### **Betaseron Subcutaneous Kit**

### **Covered Uses**

Failure of Dimethyl Fumarate and glatiramer or fingolimod for new starts

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

Betaseron is an interferon indicated to treat multiple sclerosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## Interferon gamma-1b (Actimmune)

---

### Drugs

#### Actimmune

### Covered Uses

FDA approved indications. Coverage will be based on medical history/status, antibiotic failure for chronic granulomatous disease.

### Exclusion Criteria

### Required Medical Information

### Age Restriction

Ages approved in FDA labeling/compendia

### Prescriber Restriction

Limited to specialist trained in management of prescribed condition.

### Coverage Duration

Up to 12 months

### Other Criteria

Actimmune is indicated to prevent infection in Chronic Granulomatous disease, and also delay the time to progression with severe malignant osteopetrosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## ivacaftor (Kalydeco)

---

### **Drugs**

**Kalydeco Oral Packet 25 MG, 50 MG, 75 MG, Kalydeco Oral Tablet**

### **Covered Uses**

FDA approved indications. Patient must have an FDA approved mutation.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Must be prescribed by a Pulmonologist.

#### **Coverage Duration**

12 months

#### **Other Criteria**

Kalydeco is an oral medication indicated to treat Cystic fibrosis patients with specific genetic mutations in the CFTR gene. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**  
**Ninlaro**

**Covered Uses**

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. Must have failed bortezomib.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

Must be prescribed by Oncology.

**Coverage Duration**

Up to 12 months or until disease progression or toxicity

**Other Criteria**

Ninlaro is an oral proteasome inhibitor indicated to treat relapsed or refractory multiple myeloma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **lacosamide (Vimpat)**

---

### **Drugs**

Lacosamide Oral Solution 10 MG/ML

### **Covered Uses**

FDA approved indications. Failure of Levetiracetam, topiramate, and lamotrigine.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Approved when written/ordered by a Neurologist.

#### **Coverage Duration**

12 months

#### **Other Criteria**

Vimpat is indicated as an adjunct agent used to treat partial onset seizures. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## Ianreotide (Somatuline)

---

### Drugs

#### Somatuline Depot

### Covered Uses

FDA approved indications. Failure of octreotide.

### Exclusion Criteria

### Required Medical Information

### Age Restriction

Ages approved in FDA labeling/compendia

### Prescriber Restriction

Prescriber must be an endocrinologist.

### Coverage Duration

12 months

### Other Criteria

This medication is used to treat Acromegaly. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## lanthanum carbonate (Fosrenol)

---

### **Drugs**

Lanthanum Carbonate

### **Covered Uses**

Patient has ESRD. Patient has elevated calcium on phosphate binders, or not a candidate for calcium based phosphate binders based on KDOQI guidelines. Failure of Sevelamer.

### **Exclusion Criteria**

Not covered in combination with other non-calcium based phosphate binders.

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Prescribed by a nephrologist.

#### **Coverage Duration**

12 months

#### **Other Criteria**

Fosrenol is a non-calcium based, chewable, phosphate binder indicated to manage hyperphosphatemia in ESRD. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **lapatinib (Tykerb)**

---

### **Drugs**

Lapatinib Ditosylate

### **Covered Uses**

FDA approved indications. Patient has HER2/neu + breast cancer that has failed treatment/progressed with a regimen including an anthracycline, a taxane and Herceptin. Used to treat Metastatic HR+ HER2/neu+ breast cancer in combination with an aromatase inhibitor.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Prescriber is an oncologist.

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

#### **Other Criteria**

Tykerb is indicated to treat Advanced HER2+ breast cancer in combination with Xeloda. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



## lenalidomide (Revlimid)

---

### **Drugs**

Lenalidomide

### **Covered Uses**

FDA approved indications. Patient must have failed Aranesp & Procrit for MDS anemia. Mantle cell Lymphoma requires failure of two prior treatment regimens one of which being bortezomib.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Prescriber is a hematologist/oncologist.

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

#### **Other Criteria**

Revlimid is indicated for treatment of Multiple Myeloma , Myelodysplastic syndrome, anemia that is transfusion dependent and has 5q deletion karyotype, mantle cell lymphoma Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## lenvatinib (Lenvima)

---

### Drugs

Lenvima (10 MG Daily Dose), Lenvima (12 MG Daily Dose), Lenvima (14 MG Daily Dose), Lenvima (18 MG Daily Dose), Lenvima (20 MG Daily Dose), Lenvima (24 MG Daily Dose), Lenvima (4 MG Daily Dose), Lenvima (8 MG Daily Dose)

### Covered Uses

FDA approved indications.

### Exclusion Criteria

### Required Medical Information

#### Age Restriction

Ages approved in FDA labeling/compendia

#### Prescriber Restriction

Must be written by an oncologist/hematologist.

#### Coverage Duration

Up to 12 months or until disease progression or toxicity

#### Other Criteria

Lenvima is a tyrosine kinase inhibitor indicated for several cancers. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **liraglutide (Victoza)**

---

### **Drugs**

Liraglutide

### **Covered Uses**

Covered after failure of metformin and Bydureon. Covered for use in established cardiovascular disease for patients on a Statin who have failed metformin.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

Victoza is a medication indicated for treatment of type 2 diabetes mellitus.

**Drugs**  
**Increlex**

**Covered Uses**

FDA approved indications. Coverage will be based on medical history/status, response to previous treatments, and the consideration of other therapeutic options.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

Must be prescribed by a Pediatric Endocrinologist.

**Coverage Duration**

12 months

**Other Criteria**

Increlex is indicated to treat short stature in patient with primary Insulin like Growth Factor deficiency, and patients with neutralizing antibodies to HGH. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**  
**Nucala**

**Covered Uses**

The following criteria must be met for coverage for severe eosinophilic asthma: Prescriber must be a pulmonologist or allergist. Two or more severe exacerbations in the past 12 months. Patient must fail 3 months of therapy on maximal indicated doses of Trelegy and Montelukast.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

**Prescriber Restriction**

**Coverage Duration**

12 months

**Other Criteria**

Nucala is an interleukin 5 antagonist indicated for eosinophilic asthma and eosinophilic granulomatosis with polyangiitis and nasal polyps. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Nasal Polyp indication is covered only by exception and will be based on all available treatment options including nebulized sinus treatments and devices.

## midostaurin (Rydapt)

---

### **Drugs** **Rydapt**

#### **Covered Uses**

FDA approved indications, off label use will be covered when used in alignment with NCCN recommendations of class 2A or greater.

#### **Exclusion Criteria**

#### **Required Medical Information**

##### **Age Restriction**

Ages approved in FDA labeling/compendia

##### **Prescriber Restriction**

Must be prescribed by an oncologist/hematologist.

##### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

##### **Other Criteria**

Rydapt is a kinase inhibitor indicated to treat AML, MCL, and systemic mastocytosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**

**Kynamro Subcutaneous Solution Prefilled Syringe**

**Covered Uses**

FDA approved indications. Genetic confirmation that patient is HoFH. Failure of Statin, Ezetimibe, and PCSK-9 therapy. Continuation of Kynamro after 3 month trial based on LDL reduction of at least 25% while on therapy.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

**Coverage Duration**

3 months initially, up to 12 months after response

**Other Criteria**

Kynamro is indicated to treat Homozygous Familial hypercholesterolemia Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## mirabegron (Myrbetriq)

---

### **Drugs**

Mirabegron ER

### **Covered Uses**

FDA approved indications. Failure of solifenacin, trospium, and Toviaz.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

This medication is used to treat over active bladder. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



**molnupiravir (Lagevrio)**

---

**Drugs**  
**Lagevrio**

**Covered Uses**  
All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

**Prescriber Restriction**

**Coverage Duration**  
12 months

**Other Criteria**

## nafarelin acetate (Synarel)

---

### **Drugs** **Synarel**

#### **Covered Uses**

FDA approved indications.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Approved when written by an endocrinologist or gynecologist.

#### **Coverage Duration**

Up to 12 months

#### **Other Criteria**

Synarel is a GnRH analog (intranasal formulation) indicated to treat precocious puberty in children or endometriosis in adults. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **naloxegol (Movantik)**

---

### **Drugs Movantik**

#### **Covered Uses**

FDA approved indications. Requires failure of lactulose and Miralax.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

#### **Coverage Duration**

12 months

#### **Other Criteria**

Movantik is a Peripherally Acting Mu Opioid Antagonist (PAMORA) indicated for opioid induced constipation  
Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## neratinib (Nerlynx)

---

### **Drugs** **Nerlynx**

#### **Covered Uses**

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater.

#### **Exclusion Criteria**

#### **Required Medical Information**

##### **Age Restriction**

Ages approved in FDA labeling/compendia

##### **Prescriber Restriction**

Prescriber must be a Hematologist/Oncologist

##### **Coverage Duration**

12 Months

##### **Other Criteria**

Nerlynx is indicated for extended adjuvant treatment of early stage HER2 breast cancer. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## nicotine (Nicotrol)

---

### **Drugs** **Nicotrol**

#### **Covered Uses**

Must have previously failed or have contraindication to Bupropion. Coverage is approved for 24 weeks of treatment. Copayment will be applied per package.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

#### **Coverage Duration**

24 weeks

#### **Other Criteria**

Indicated for smoking cessation therapy. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## nilotinib (Tasigna)

---

### **Drugs** **Tasigna**

#### **Covered Uses**

FDA approved indications. Covered for treatment failure with dasatinib.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

#### **Other Criteria**

Tasigna is an oral antineoplastic agent used to treat Philadelphia Chromosome + CML Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**

**Zejula Oral Capsule**

**Covered Uses**

FDA approved indications, off label use will be covered when used in alignment with NCCN recommendations of class 2A or greater.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

Must be prescribed by an oncologist/hematologist.

**Coverage Duration**

Up to 12 months or until disease progression or toxicity

**Other Criteria**

Zejula is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## ocrelizumab (Ocrevus)

---

### **Drugs** **Ocrevus**

#### **Covered Uses**

FDA approved indications. For Relapsing Remitting Multiple Sclerosis must have failed Dimethyl Fumarate or Glatiramer

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Must be prescribed by a neurologist.

#### **Coverage Duration**

12 months

#### **Other Criteria**

Ocrevus is a CD20-directed cytolytic antibody indicated for the treatment of relapsing remitting or primary progressive forms of multiple sclerosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



## olanzapine (Zyprexa)

---

### **Drugs**

**Zyprexa Relprevv**

### **Covered Uses**

FDA approved indications. Failure of oral aripiprazole and olanzapine.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

Approved when written/ordered by a Psychiatrist or Neurologist through referrals for new starts.

### **Coverage Duration**

12 months

### **Other Criteria**

Zyprexa Relprevv is a psychotropic medication. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

## olaparib (Lynparza)

---

### **Drugs**

#### **Lynparza Oral Tablet**

### **Covered Uses**

Lynparza is used to treat BRCA+ ovarian or breast cancers.

### **Exclusion Criteria**

Progression on a PARP inhibitor

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Restricted to Hematology/Oncology.

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

#### **Other Criteria**

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**  
**Xolair**

**Covered Uses**

•Xolair is an anti-IgE monoclonal antibody indicated for patients 12 years and older with moderate to severe persistent asthma who have a positive skin test or in-vitro reactivity to an aeroallergen and chronic idiopathic urticaria. Xolair was not studied in patients who smoke. •Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. •Nasal Polyp indication is covered only by exception and will be based on all available treatment options including nebulized sinus treatments and devices The following criteria must be met for coverage for severe asthma: •Prescriber must be a pulmonologist or allergist. •Patient must have baseline IGE levels within indicated range for Xolair labeling. •Patient must test positive to an aeroallergen (either skin test or blood test). •Patient must fail 3 months of therapy on maximal indicated doses of Trelegy. •Patient must have failed leukotriene receptor antagonist The following criteria must be met for coverage for chronic idiopathic urticaria: •Prescribed by an allergist, immunologist, or dermatologist •Patient must have a diagnosis of chronic idiopathic urticaria (at least a 6 week history) •Patient must have tried, for a minimum of 2 weeks and failed 2 of the following antihistamines at maximal doses used to treat CIU: cetirizine(40mg/day), levocetirizine (20mg/day), desloratadine(20mg/day), fexofenadine (540mg/day), loratadine (40mg/day) with MONTELUKAST AND trial Dicyclomine or Hydroxyzine

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

**Coverage Duration**

12 months

**Other Criteria**

## Omnipod/ Omnipod Dash

---

### **Drugs**

Omnipod 5 DexG7G6 Intro Gen 5, Omnipod 5 DexG7G6 Pods Gen 5, Omnipod 5 G7 Intro (Gen 5), Omnipod 5 G7 Pods (Gen 5), Omnipod Classic Pods (Gen 3), Omnipod DASH Pods (Gen 4)

### **Covered Uses**

Omnipod and Omnipod Dash are covered for Type 1 diabetics who meet MCG (Milliman Coverage Guideline) criteria

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician

## onabotulinumtoxinA (Botox)

---

### **Drugs**

#### **Botox**

### **Covered Uses**

Non-Cosmetic FDA approved indications

### **Exclusion Criteria**

FDA labeled contraindications, and excluded for cosmetic conditions

### **Required Medical Information**

Medical notes, previous treatment history and associated studies

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

FHCP covers this medication only for medically necessary purposes, like cervical dystonia, not responsive to physical therapy, blepharospasm that interferes significantly with vision, and headache not responsive to preventive and acute therapy by Neurology for at least 16 weeks

**Drugs**  
**Tagrisso**

**Covered Uses**

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. Must possess the t790m mutation if being used after progression on an EGFR tyrosine kinase inhibitor.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

**Coverage Duration**

Up to 12 months or until disease progression or toxicity

**Other Criteria**

Tagrisso is indicated to treat patients with metastatic non-small cell lung cancer who possess an EGFR mutation. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## oxandrolone (Oxandrin)

---

### **Drugs**

Oxandrolone Oral

### **Covered Uses**

FDA approved indications.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Approved when written by Oncology, through referrals.

#### **Coverage Duration**

up to 12 months

#### **Other Criteria**

Oxandrin is an anabolic steroid indicated for weight gain in cachexia. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## oxymetholone (Anadrol-50)

---

### **Drugs**

#### **Anadrol-50**

### **Covered Uses**

FDA approved indications. Medical history and information reviewed by referrals. Coverage will be response to previous treatments, and the consideration of other therapeutic options (ESAs, B12/folate, iron).

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

### **Coverage Duration**

Up to 12 months

### **Other Criteria**

Anadrol is an anabolic steroid indicated to treat various types of anemia. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



**Drugs**  
**Ibrance**

**Covered Uses**

FDA approved indications. Diagnosis Metastatic ER+ HER- Breast cancer.

**Exclusion Criteria**

Progression on a CDK 4/6 inhibitor

**Required Medical Information**

Medical notes, previous treatment history and associated studies, including diagnosis of metastatic ER+ HER- breast cancer.

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

Must be prescribed by Hematologist/oncologist.

**Coverage Duration**

Up to 12 months or until disease progression or toxicity

**Other Criteria**

Ibrance is a CDK 4/6 inhibitor indicated for first-line/second line treatment of metastatic ER+/HER- breast cancer used in combination with an aromatase inhibitor Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## paliperidone (Invega Sustenna) injection

---

### **Drugs**

**Invega Sustenna Intramuscular Suspension Prefilled Syringe**

### **Covered Uses**

FDA approved indications. Failure of oral aripiprazole, paliperidone and risperidone.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

Approved when written/ordered by a Psychiatrist or Neurologist through referrals.

### **Coverage Duration**

12 months

### **Other Criteria**

Invega Sustenna is a psychotropic medication. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

## panobinostat (Farydak)

---

### **Drugs** **Farydak**

**Covered Uses**  
FDA approved indications.

### **Exclusion Criteria**

### **Required Medical Information**

**Age Restriction**  
Ages approved in FDA labeling/compendia

**Prescriber Restriction**  
Must be written by an oncologist.

**Coverage Duration**  
Up to 12 months or until disease progression or toxicity

**Other Criteria**  
Farydak is indicated to treat multiple myeloma in patients who have received at least two therapies including Velcade and an immunomodulatory agent. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## pazopanib (Votrient)

---

### **Drugs**

PAZOPanib HCl

### **Covered Uses**

Votrient is an oral tyrosine kinase inhibitor indicated to treat Renal cell carcinoma, and soft tissue sarcoma.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Prescribing restricted to oncology.

#### **Coverage Duration**

12 months

#### **Other Criteria**

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **PegFilgrastim**

---

### **Drugs**

**Fulphila, Udenyca, Udenyca Onbody**

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

6 months

### **Other Criteria**

All FDA approved uses, Off-Label uses must be NCCN supported with a grade 2a recommendation or greater.

## peginterferon alfa-2b (Sylatron)

---

### Drugs

**Sylatron Subcutaneous Kit 200 MCG, 300 MCG, 600 MCG**

### Covered Uses

FDA approved indications. Must be used as adjuvant treatment within 84 days of surgical resection in patients with metastatic melanoma with nodal involvement.

### Exclusion Criteria

### Required Medical Information

#### Age Restriction

Ages approved in FDA labeling/compendia

#### Prescriber Restriction

Prescriber must be an oncologist.

#### Coverage Duration

Up to 12 months

#### Other Criteria

Sylatron is an adjuvant treatment for metastatic melanoma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## penicillamine (Cuprimine)

---

### **Drugs**

Penicillamine Oral Capsule

### **Covered Uses**

FDA approved indications. Coverage for Rheumatoid Arthritis requires failure of a TNF Agent, and a JAK inhibitor or Abatacept.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Written by a Rheumatologist, or Neurologist, or Urologist or Hepatologist.

#### **Coverage Duration**

12 Months

#### **Other Criteria**

Cuprimine is indicated for treatment of Rheumatoid arthritis, Wilsons Disease and cystinuria. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## pentamidine isothionate (Nebupent) nebulized

---

### **Drugs**

Pentamidine Isethionate Inhalation

### **Covered Uses**

Failure of topical ketoconazole, econazole, clotrimazole betamethasone, nystatin triamcinolone.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

Nebupent is a inhaled solution used to treat PCP pneumonia. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



## perampanel (Fycompa)

---

### Drugs

#### Fycompa Oral Tablet

### Covered Uses

Written by a neurologist for treatment of seizures. Failure of Levetiracetam, topiramate, and lamotrigine.

### Exclusion Criteria

### Required Medical Information

#### Age Restriction

Ages approved in FDA labeling/compendia

#### Prescriber Restriction

Written by a neurologist.

### Coverage Duration

12 months

### Other Criteria

Fycompa is an anti-convulsant indicated for adjunctive treatment of partial seizures. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **pirfenidone (Esbriet)**

---

### **Drugs**

Pirfenidone

### **Covered Uses**

Pirfenidone is indicated for idiopathic pulmonary fibrosis. Medical history and studies are reviewed in Referrals and if approved will notify the physician. Criteria for coverage as follows: Confirmed diagnosis of IPF by high resolution CT or surgical biopsy. Prescribed by a pulmonologist

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

pulmonologist

### **Coverage Duration**

12 months

### **Other Criteria**

## **pomalidomide (Pomalyst)**

---

### **Drugs**

#### **Pomalyst**

### **Covered Uses**

FDA approved indications, Off label use must be supported by NCCN with evidence rating of 2a or greater. Coverage requires failure of Revlimid and Velcade.

### **Exclusion Criteria**

### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Restricted to Hematology/Oncology.

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

#### **Other Criteria**

Pomalyst is thalidomide analog used to treat refractory Multiple Myeloma Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## ponatinib (Iclusig)

---

### **Drugs** **Iclusig**

#### **Covered Uses**

FDA approved indications.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Must be prescribed by Hematologist/oncologist.

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

#### **Other Criteria**

Iclusig is a tyrosine Kinase inhibitor indicated to treat Chronic Myelogenous Leukemia. Coverage will be based on failure of first or second line TKI for CML or presence of T350I mutation. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## posaconazole (Noxafil)

---

### Drugs

**Noxafil Oral Suspension**, Posaconazole Oral Tablet Delayed Release

### Covered Uses

FDA approved indications. Organism must be resistant to itraconazole, voriconazole, and fluconazole.

### Exclusion Criteria

### Required Medical Information

#### Age Restriction

Ages approved in FDA labeling/compendia

#### Prescriber Restriction

#### Coverage Duration

3 months

#### Other Criteria

Noxafil is an anti-fungal indicated for aspergillus and Candida in immunocompromised patients. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **pramlintide acetate (Symlin)**

---

### **Drugs**

**SymlinPen 120 Subcutaneous Solution Pen-Injector, SymlinPen 60 Subcutaneous Solution Pen-Injector**

### **Covered Uses**

FDA approved indications. Patient is uncontrolled despite optimal insulin utilization with Ha1c between 7%-9%. Not for use in patients with gastroparesis.

### **Exclusion Criteria**

### **Required Medical Information**

Medical notes, previous treatment history, and labs, including HA1c

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

Prescriber is an endocrinologist.

### **Coverage Duration**

12 months

### **Other Criteria**

Symlin is indicated to treat Type 1 and 2 Diabetes. Symlin is indicated for adjunctive treatment of DM with insulin. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **pyrimethamine (Daraprim)**

---

### **Drugs**

Pyrimethamine Oral

### **Covered Uses**

Toxoplasmosis. Patient must have failed compounded pyrimethamine

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

### **Coverage Duration**

12 Months

### **Other Criteria**

Daraprim is used to treat toxoplasmosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## regorafenib (Stivarga)

---

### **Drugs** **Stivarga**

#### **Covered Uses**

Stivarga is an oral tyrosine kinase inhibitor indicated to treat Colorectal cancer and , Hepatocellular carcinoma.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Prescribing restricted to oncology.

#### **Coverage Duration**

12 Months

#### **Other Criteria**

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



**Drugs**

Kisqali (200 MG Dose), Kisqali (400 MG Dose), Kisqali (600 MG Dose), Kisqali 200 Dose, Kisqali 400 Dose, Kisqali 600 Dose, Kisqali Femara (200 MG Dose), Kisqali Femara (400 MG Dose), Kisqali Femara (600 MG Dose)

**Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria**

**Required Medical Information**

Diagnosis Metastatic ER+ HER- Breast cancer.

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

Hematologist/Oncologist

**Coverage Duration**

Up to 12 months or until disease progression or toxicity

**Other Criteria**

Kisqali is a CDK 4/6 inhibitor indicated for first-line/second line treatment of metastatic ER+/HER- breast cancer used in combination with an aromatase inhibitor, or early stage breast cancer (HR+ HER2-) stage 2 or 3 with high risk of recurrence. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**

**Xifaxan**

**Covered Uses**

All FDA-approved indications not otherwise excluded from Part D. Criteria for coverage as follows:

- For the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults:
- Must have tried and failed adequate doses of the following:
  - o Cholestyramine
  - o Loperamide
  - o dicyclomine (which may be dosed up to 40 mg PO 4 times daily) or Hyoscyamine ER
  - o Amitriptyline AND
  - o Diphenoxylate-Atropine or Clordiazepoxide-Clidinium.
- Treatment is limited to 14 days, recurrence will require a renewal of authorization and limited to 2 treatments.

For the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults:

- Lactulose dosed 30 to 45 mL (20 to 30 g) PO 3 to 4 times daily with clinical documentation to support overt hepatic encephalopathy

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

Gastroenterologist

**Coverage Duration**

Up to 12 months for HE. 14 days for IBS-D

**Other Criteria**

Xifaxan is a non systemic oral antibiotic used to treat hepatic encephalopathy and Irritable Bowel Syndrome. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **rilonacept (Arcalyst)**

---

### **Drugs Arcalyst**

#### **Covered Uses**

Diagnosis of CAPS and Documentation of disability due to the condition, failure of anakinra, and nsaid.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Prescribing limited to immunologist.

#### **Coverage Duration**

Up to 12 months

#### **Other Criteria**

Arcalyst is indicated to treat Cryopyrin Associated Periodic Syndromes (CAPS). Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

## risperidone (Risperdal Consta) injection

---

### **Drugs**

risperiDONE Microspheres ER

### **Covered Uses**

FDA approved indications. Failure of oral aripiprazole and risperidone.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

Approved when written/ordered by a Psychiatrist or Neurologist through referrals.

### **Coverage Duration**

12 months

### **Other Criteria**

Risperdal Consta is a psychotropic medication. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

## rotigotine (Neupro)

---

### **Drugs** **Neupro**

#### **Covered Uses**

FDA approved indications. Failure of Ropinirole and Pramipexole.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

#### **Coverage Duration**

12 months

#### **Other Criteria**

Neupro is a transdermal dopamine agonist indicated for treatment of Parkinsons disease. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **rufinamide (Banzel)**

---

### **Drugs**

Rufinamide

### **Covered Uses**

FDA approved indications

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

Ages approved in FDA labeling/compendia

### **Prescriber Restriction**

Approved when written/ordered by a Neurologist for seizures through referrals.

### **Coverage Duration**

12 months

### **Other Criteria**

Banzel is indicated for treatment of Lennox Gastaut syndrome. Prior authorization only applies to existing members who are new starts on the drug. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.

**Drugs**  
**Jakafi**

**Covered Uses**

FDA approved indications. Not used in combination with lenalidomide/thalidomide, other JAK or TKI inhibitors. Continuation in therapy will require 50% reduction in baseline spleen size, or 35% reduction in spleen volume, or a 50% reduction in baseline Myelofibrosis symptom score.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

Ages approved in FDA labeling/compendia

**Prescriber Restriction**

Prescriber is a hematologist/oncologist.

**Coverage Duration**

Up to 12 months or until disease progression or toxicity

**Other Criteria**

Jakafi is an oral JAK inhibitor indicated for treatment of intermediate to high risk myelofibrosis including primary myelofibrosis, polycythemia vera, myelofibrosis, and essential thrombocythemia myelofibrosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**

**Entresto Oral Tablet**

**Covered Uses**

All FDA-approved indications not otherwise excluded from Part D. For Heart Failure with reduced ejection fraction (less than or equal to 40%) For initiation: eGFR greater than or equal to 30ml/min and K+ less than 5.0 meq/l for initiation Patient has NYHA Class II-IV symptoms Approve for 3 months initially For continuation: Member is at target dose approve for 12 months Member is below Entresto target dose THEN Approve for 3 months if member is tolerating dose but has not had a titration attempt and SBP greater than 100 OR Approve for 12 months if member has failed titration attempt or SBP less than 100 For Heart Failure with preserved ejection fraction For initiation: Patient has an ejection fraction less than or equal to 55% NYHA Class II-IV symptoms Currently taking an SGLT-2 inhibitor eGFR greater than 30 ml/min Approve for 3 months initially For continuation: Member is at target dose approve for 12 months Member is below Entresto target dose THEN Approve for 3 months if member is tolerating dose but has not had a titration attempt and SBP greater than 100 OR Approve for 12 months if member has failed titration attempt or SBP less than 100

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

**Prescriber Restriction**

**Coverage Duration**

12 months

**Other Criteria**

Entresto is a medication used for treatment of Heart Failure. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy.



**Drugs**  
**Kevzara**

**Covered Uses**

Kevzara is an injectible Il-6 antagonist indicated for rheumatoid arthritis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Criteria for coverage as follows: Coverage is limited to Rheumatoid arthritis. Must fail a preferred specialty agent (Enbrel, Xeljanz, Hadlima) Must have clear documentation of moderate to severe rheumatoid arthritis

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

**Prescriber Restriction**

**Coverage Duration**

12 months

**Other Criteria**

## **sildenafil (Revatio)**

---

### **Drugs**

Sildenafil Citrate Oral Tablet 20 MG

### **Covered Uses**

FDA approved indications. Pulmonary hypertension must be diagnosed by heart catheterization. Evaluation, EKG, catheterization results and an objective test of exercise ability (6 minute walk) must be submitted with referral.

### **Exclusion Criteria**

This medication is contraindicated in patients using organic nitrates either regularly or intermittently

### **Required Medical Information**

#### **Age Restriction**

#### **Prescriber Restriction**

#### **Coverage Duration**

12 months

### **Other Criteria**

Revatio is indicated for the treatment of Primary pulmonary hypertension or pulmonary hypertension related to connective tissue disease. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**  
**Januvia**

**Covered Uses**

FDA approved indications. Patient must be on maximal doses of Metformin and Sulfonylurea or other combination therapy if metformin contraindicated for at least 6 months, or have intolerance/contraindication. Failure of Onglyza.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

**Prescriber Restriction**

**Coverage Duration**

12 months

**Other Criteria**

Januvia is an oral anti-diabetic agent used to treat Type 2 Diabetes (DPP-IV inhibitor). Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **sodium oxybate (Xyrem)**

---

### **Drugs**

Sodium Oxybate

### **Covered Uses**

Only covered for Narcolepsy with cataplexy. Coverage will be based on recent failure of Modafinil AND Armodafinil AND Amphetamine/Dextroamphetamine And soriamfetol. Tricyclic Antidepressant shown to be effective in cataplexy (Clomipramine/Protriptyline) and Venlafaxine (for cataplexy) Three month discontinuation trials for moderate to highly sedating medications such as benzodiazepines, opioids, anticholinergics, muscle relaxers, atypical antipsychotics, dopamine agonists.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

Must be prescribed by physician board certified in sleep medicine.

### **Coverage Duration**

Up to 12 months

### **Other Criteria**

This medication is used for treatment of narcolepsy with cataplexy or excessive daytime sleepiness due to narcolepsy. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## sodium zirconium cyclosilicate (Lokelma)

---

### **Drugs**

#### **Lokelma**

### **Covered Uses**

Hyperkalemia after discontinuation trial of potassium sparing medications, trial of a loop diuretic if clinically indicated.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

Lokelma is indicated for the treatment of hyperkalemia. Medical history and studies are reviewed in referrals and if approved will notify pharmacy and the physician.

## somatropin (Omnitrope)

---

### **Drugs**

**Omnitrope Subcutaneous Solution Cartridge, Omnitrope Subcutaneous Solution Reconstituted**

### **Covered Uses**

FDA approved indications. This information with the lab attached is sent to the Referrals Department.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

Growth Hormone is a pituitary hormone used for endogenous HGH deficiencies Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## sonidegib (Odomzo)

---

### **Drugs** **Odomzo**

**Covered Uses**  
FDA approved indications.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

**Prescriber Restriction**  
Must be prescribed by Oncology.

**Coverage Duration**  
Up to 12 months or until disease progression or toxicity

**Other Criteria**  
Odomzo is an oral oncology agent indicated to treat locally advanced basal cell carcinoma which has recurred following radiation or surgery. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **sorafenib (Nexavar)**

---

### **Drugs**

SORafenib Tosylate

### **Covered Uses**

Nexavar is an oral tyrosine kinase inhibitor indicated to treat Renal cell carcinoma, Hepatocellular carcinoma, and thyroid carcinoma.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

Prescribing restricted to oncology.

### **Coverage Duration**

12 months

### **Other Criteria**

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



## **sunitinib (Sutent)**

---

### **Drugs**

SUNItinib Malate

### **Covered Uses**

Sutent is an oral tyrosine kinase inhibitor indicated to treat Renal cell carcinoma, Gastrointestinal Stromal Tumors, and pancreatic neuroendocrine tumors.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

Prescribing restricted to oncology.

### **Coverage Duration**

12 Months

### **Other Criteria**

Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## Sunosi

---

### Drugs

**Sunosi Oral Tablet 150 MG, 75 MG**

### Covered Uses

Sunosi is a dopamine and norepinephrine inhibitor indicated for treatment of excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea. Coverage is limited to indication of Narcolepsy Criteria for coverage as follows: Failure of Modafinil and Armodafinil

### Exclusion Criteria

### Required Medical Information

### Age Restriction

### Prescriber Restriction

Board Certified Sleep Medicine

### Coverage Duration

12 months

### Other Criteria

## **tadalafil (Adcirca)**

---

### **Drugs**

Tadalafil (PAH)

### **Covered Uses**

FDA approved indications. Pulmonary hypertension must be diagnosed by right heart catheterization. Evaluation, EKG, catheterization results and an objective test of exercise ability (6 minute walk) must be submitted with referral.

### **Exclusion Criteria**

This medication is contraindicated in patients using organic nitrates either regularly or intermittently.

### **Required Medical Information**

#### **Age Restriction**

#### **Prescriber Restriction**

#### **Coverage Duration**

12 months

### **Other Criteria**

Adcirca is indicated for treatment of pulmonary arterial hypertension (WHO group 1). Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **tazarotene (Tazorac)**

---

### **Drugs**

Tazarotene External Cream, Tazarotene External Gel

### **Covered Uses**

FDA approved indications. For Psoriasis patient must have failed medium to high potency topical corticosteroid. For acne patient must have failed adapalene or tretinoin or oral tetracycline class antibiotic.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

Must be written by dermatology.

### **Coverage Duration**

12 months

### **Other Criteria**

Tazorac is a topical retinoid indicated to treat Acne or Psoriasis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## Teriflunomide

---

### Drugs

Teriflunomide

### Covered Uses

Teriflunimide is indicated to treat Multiple Sclerosis. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Criteria for coverage as follows: FDA approved indications. Prescriber must be a neurologist.

### Exclusion Criteria

### Required Medical Information

### Age Restriction

### Prescriber Restriction

### Coverage Duration

12 months

### Other Criteria

## teriparatide (Forteo)

---

### Drugs

Teriparatide Subcutaneous Solution Pen-Injector 620 MCG/2.48ML

### Covered Uses

FDA approved indications.

### Exclusion Criteria

FDA labeled contraindications. Exclusions also include use in children, adolescents, Paget's patients with Paget's disease or hypercalcemia, or patients with a history of primary or metastatic bone cancer.

### Required Medical Information

Medical notes, previous treatment history and associated studies, including BMD, Vit D, Calcium, and iPTH.

### Age Restriction

Ages approved in FDA labeling/compendia

### Prescriber Restriction

### Coverage Duration

12 months, but limited to total treatment duration of 2 years.

### Other Criteria

Patient must be diagnosed with osteoporosis with a BMD less than -2.5. Patient must have failed treatment with IV bisphosphonate and denosumab. For Patients with calculated GFR or CRcl ; 60ml/min, referral must include recent iPTH. Vitamin D (25 OH, 1,25 OH) must be within normal limits.

## tetrabenazine (Xenazine)

---

### **Drugs**

Tetrabenazine

### **Covered Uses**

FDA approved indications. Patient must have moderate to severe chorea that is refractory to amantadine, neuroleptics or anticonvulsants.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

Prescriber must be a neurologist.

### **Coverage Duration**

12 months

### **Other Criteria**

Xenazine is indicated to treat chorea associated with Huntingtons disease. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **tetrahydrocannabinol (Marinol)**

---

### **Drugs**

Dronabinol

### **Covered Uses**

For cachexia, patient must fail megestrol acetate. For nausea and vomiting patient must fail Ondansetron and Emend.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

Dronabinol is indicated to treat HIV/Cancer related Cachexia and chemotherapy induced nausea and vomiting. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



## thalidomide (Thalomid)

---

### **Drugs** **Thalomid**

**Covered Uses**  
FDA approved indications.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

**Prescriber Restriction**  
Approved when written by Oncology, Infectious Disease or in HIV through referrals.

**Coverage Duration**  
12 months

**Other Criteria**  
Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**  
**Lonsurf**

**Covered Uses**

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

**Prescriber Restriction**

Must be prescribed by an Oncologist

**Coverage Duration**

Up to 12 months or until disease progression or toxicity

**Other Criteria**

Lonsurf is indicated to treat patients with metastatic colorectal cancer who have progressed on two to three lines of treatment. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**

**Xeljanz Oral Solution, Xeljanz Oral Tablet, Xeljanz XR**

**Covered Uses**

FDA approved indications. For rheumatoid arthritis must be written by Rheumatology, Patient must fail adequate trial of MTX in combination with a DMARD If MTX contraindicated, must try combination of 2- nonbiologic DMARDS (3 month trial in past 6 months) and a preferred TNF. For Psoriatic Arthritis Patient must fail adequate trial of MTX or LEF in past 6 months. For with ulcerative colitis must be written by a gastroenterologist and had recent failure of an immunosuppressant (Azathioprine, 6-mp or Methotrexate) and an anti-inflammatory (5-asa, sulfasalazine, balsalazide, mesalamine)

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

**Prescriber Restriction**

For rheumatoid arthritis must be written by Rheumatology. For with ulcerative colitis must be written by a gastroenterologist.

**Coverage Duration**

Up to 12 months

**Other Criteria**

Xeljanz is indicated for treatment of Moderate to severe Rheumatoid arthritis in adults, Psoriatic Arthritis, Ulcerative colitis, JIA. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## trametinib (Mekinist)

---

### Drugs

#### Mekinist Oral Tablet

### Covered Uses

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. Patient must have BRAF V600E/K mutation.

### Exclusion Criteria

### Required Medical Information

### Age Restriction

### Prescriber Restriction

Must be written by an oncologist.

### Coverage Duration

Up to 12 months or until disease progression or toxicity

### Other Criteria

Mekinist is a MEK inhibitor indicated to treat BRAF+ V600e/k mutation Stage IIIc-IV metastatic Melanoma and NSCLC. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## tretinoin ()

---

### **Drugs**

Tretinoin Oral

### **Covered Uses**

FDA approved indications.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

Approved when written by Oncology through referrals.

### **Coverage Duration**

12 months

### **Other Criteria**

Vesanoid is indicated to treat promyelocytic leukemia. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **tretinoin (Retin-A)**

---

### **Drugs**

Tretinoin External Cream, Tretinoin External Gel 0.01 %, 0.025 %

### **Covered Uses**

Tretinoin is indicated to treat moderate to severe acne and diseases of keratinization such as ichthyosis and keratosis follicularis. Prior authorization only required for patients greater than 30 years of age. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician. Criteria for coverage as follows: FDA approved indications. This medication is not covered for wrinkles or photo aging.

### **Exclusion Criteria**

This medication is not covered for wrinkles or photo aging.

### **Required Medical Information**

#### **Age Restriction**

Prior authorization only required for patients greater than 30 years of age.

#### **Prescriber Restriction**

#### **Coverage Duration**

12 months

#### **Other Criteria**

**Drugs**

**Yesintek Subcutaneous**

**Covered Uses**

Stelara is indicated for treatment of moderate to severe plaque psoriasis and psoriatic arthritis and Crohn's disease. Medical history and studies are reviewed in Referrals and if approved will notify the physician. Criteria for coverage as follows: FDA approved indications only at FDA approved doses • Prescribed by a dermatologist or Rheumatologist. • Only covered as a medical benefit. • Notes supporting moderate to severe Plaque psoriasis or Psoriatic arthritis • For Plaque Psoriasis, recent failure (in past 6 months) of methotrexate . • For Psoriatic Arthritis failure of methotrexate and adalimumab or xeljanz • For Crohns Disease must fail conventional agents Renflexis • For Ulcerative Colitis must fail, Renflexis or Xeljanz, (when clinically appropriate) with 5-ASA anti-inflammatory.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

**Prescriber Restriction**

**Coverage Duration**

Up to 12 months

**Other Criteria**

## **vandetanib (Caprelsa)**

---

### **Drugs Caprelsa**

#### **Covered Uses**

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

#### **Prescriber Restriction**

Prescriber must be a Hematologist/Oncologist.

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

#### **Other Criteria**

Caprelsa medication indicated for treatment of metastatic medullary thyroid cancer. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



## **vemurafenib (Zelboraf)**

---

### **Drugs Zelboraf**

#### **Covered Uses**

FDA approved indications, off label use will be covered when there is an NCCN supported indication with a recommendation of class 2A or greater. Patient must have BRAF V600E/K mutation.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

#### **Prescriber Restriction**

Must be written by an oncologist.

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

#### **Other Criteria**

Zelboraf is a BRAF inhibitor indicated to treat BRAF+ V600e/k mutation Stage IIIc-IV metastatic Melanoma, NSCLC, and Metastatic colorectal cancer. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## venetoclax (Venclexta)

---

### Drugs

Venclexta, Venclexta Starting Pack

### Covered Uses

FDA approved indications.

### Exclusion Criteria

### Required Medical Information

### Age Restriction

### Prescriber Restriction

Restricted to Hematology/Oncology.

### Coverage Duration

Up to 12 months or until disease progression or toxicity

### Other Criteria

Venclexta is a BCL-2 inhibitor indicated for treatment of BCell Lymphomas. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

**Drugs**  
**Erivedge**

**Covered Uses**

FDA approved indications. Patient has Metastatic basal cell cancer, or recurrent basal cell cancer, or who are not candidates for surgery and not candidates for radiation.

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

**Prescriber Restriction**

Prescriber is a hematologist/oncologist.

**Coverage Duration**

Up to 12 months or until disease progression or toxicity

**Other Criteria**

Erivedge is indicated for treatment of metastatic or locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and are not candidates for radiation. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **voriconazole (Vfend)**

---

### **Drugs**

Voriconazole Oral

### **Covered Uses**

FDA approved indications. Two of the following medications have been tried, unless resistance or contraindication precludes use, Itraconazole, fluconazole, ketoconazole. Exclusions to pre-requisite medications are Invasive pulmonary aspergillosis, *Scedosporium apiospermum*, and *fusarium*.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

Voriconazole is an antifungal medication used to treat aspergillosis and other invasive fungal infections. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **vorinostat (Zolinza)**

---

### **Drugs Zolinza**

#### **Covered Uses**

FDA approved indications. Failed minimum of two systemic treatments, one of which must be Targretin, unless contraindicated.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

#### **Prescriber Restriction**

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

#### **Other Criteria**

Zolinza is indicated for cutaneous manifestations of cutaneous T-cell Lymphoma Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **vortioxetine (Trintellix)**

---

### **Drugs** **Trintellix**

#### **Covered Uses**

FDA approved indications. Failure or intolerance to two generically available anti-depressants in past 6 months.

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

#### **Prescriber Restriction**

#### **Coverage Duration**

12 months

#### **Other Criteria**

Trintellix is an antidepressant used to treat major depressive disorder. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## zanubrutinib (Brukinsa)

---

### **Drugs** **Brukinsa**

#### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D. NCCN supported use with evidence rating 2a or greater

#### **Exclusion Criteria**

#### **Required Medical Information**

#### **Age Restriction**

Ages approved in FDA labeling/compendia

#### **Prescriber Restriction**

Hematologist/Oncologist

#### **Coverage Duration**

Up to 12 months or until disease progression or toxicity

#### **Other Criteria**

Brukinsa is a BTK inhibitor used to treat B cell lymphomas. It is indicated for relapsed refractory chronic lymphocytic leukemia and Mantle Cell Lymphoma, and first line CLL. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.

## **zileuton (Zyflo)**

---

### **Drugs**

Zileuton ER

### **Covered Uses**

FDA approved indications. Uncontrolled Asthma while on maximal doses of long acting bronchodilators and inhaled corticosteroids AND montelukast. 6 months of medication compliance with maintenance treatments.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

Must be written by a pulmonologist.

### **Coverage Duration**

12 months

### **Other Criteria**

Zyflo is indicated for treatment of asthma. Medical history and studies are reviewed in Referrals and if approved will notify pharmacy and the physician.



<b>Index</b>		
<b>Abilify Maintena Intramuscular Prefilled Syringe</b> .....	11	
Abiraterone Acetate Oral Tablet 250 MG.....	2	
<b>Actimmune</b> .....	65	
<b>Aimovig</b> .....	42	
<b>Alecensa</b> .....	5	
Ambrisentan.....	7	
<b>Anadrol-50</b> .....	95	
Aprepitant Oral Capsule.....	10	
<b>Aptiom</b> .....	44	
<b>Arcalyst</b> .....	114	
<b>Avonex Pen Intramuscular Auto-Injector Kit</b> .....	62	
<b>Avonex Prefilled Intramuscular Prefilled Syringe Kit</b> .....	62	
<b>Baqsimi One Pack</b> .....	54	
<b>Benefix Intravenous Kit</b> .....	14	
<b>Berinert</b> .....	17	
<b>Betaseron Subcutaneous Kit</b> .....	64	
Bosentan.....	15	
<b>Bosulif Oral Tablet</b> .....	16	
<b>Botox</b> .....	92	
<b>Brukinsa</b> .....	150	
<b>Caprelsa</b> .....	143	
Cinacalcet HCl.....	20	
Clobazam Oral Suspension 2.5 MG/ML.....	21	
Clobazam Oral Tablet.....	21	
<b>Cometriq (100 MG Daily Dose) Oral Kit 80 &amp; 20 MG</b> .....	18	
<b>Cometriq (140 MG Daily Dose) Oral Kit 3 x 20 MG &amp; 80 MG</b> .....	18	
<b>Cometriq (60 MG Daily Dose)</b> ....	18	
<b>Cotellic</b> .....	22	
Dalfampridine ER.....	25	
Dasatinib.....	27	
Deferasirox Oral Tablet Soluble..	28	
Dimethyl Fumarate Oral.....	32	
Dimethyl Fumarate Starter Pack Oral.....	32	
Dronabinol.....	135	
<b>Emend Oral Suspension Reconstituted</b> .....	10	
<b>Emgality</b> .....	52	
<b>Emgality (300 MG Dose)</b> .....	52	
<b>Enbrel Mini</b> .....	46	
<b>Enbrel Subcutaneous Solution 25 MG/0.5ML</b> .....	46	
<b>Enbrel Subcutaneous Solution Prefilled Syringe</b> .....	46	
<b>Enbrel Subcutaneous Solution Reconstituted</b> .....	46	
<b>Enbrel SureClick Subcutaneous Solution Auto-Injector</b> .....	46	
<b>Entresto Oral Tablet</b> .....	119	
<b>Erivedge</b> .....	146	
<b>Erleada</b> .....	9	
Erlotinib HCl.....	43	
Everolimus Oral Tablet.....	47, 48	
<b>Fanapt</b> .....	60	
<b>Fanapt Titration Pack</b> .....	60	
<b>Farydak</b> .....	98	
fentaNYL Citrate Buccal Lozenge On A Handle.....	49	
Fentanyl Transdermal Patch 72 Hour 100 MCG/HR, 12 MCG/HR, 25 MCG/HR, 50 MCG/HR, 75 MCG/HR.....	50	
Fingolimod HCl.....	51	
<b>Firmagon</b> .....	29	
<b>Fulphila</b> .....	100	
<b>Fycompa Oral Tablet</b> .....	104	
Gefitinib.....	53	
<b>Gilotrif</b> .....	4	
<b>Hadlima</b> .....	3	
<b>Hadlima PushTouch</b> .....	3	
<b>Humulin R U-500 (Concentrated)</b> .....	56	
<b>Humulin R U-500 KwikPen Subcutaneous Solution Pen-Injector</b> .....	56	
<b>Ibrance</b> .....	96	
<b>Iclusig</b> .....	107	
<b>Idhifa</b> .....	38	
<b>Imbruvica Oral Capsule</b> .....	57	
<b>Imbruvica Oral Suspension</b> .....	58	
<b>Imbruvica Oral Tablet 420 MG, 560 MG</b> .....	57	
<b>Increlex</b> .....	75	
<b>Inlyta</b> .....	13	
<b>Invega Sustenna Intramuscular Suspension Prefilled Syringe</b> .....	97	
<b>Jakafi</b> .....	118	
<b>Januvia</b> .....	122	
<b>Kalydeco Oral Packet 25 MG, 50 MG, 75 MG</b> .....	66	
<b>Kalydeco Oral Tablet</b> .....	66	
<b>Kevzara</b> .....	120	
<b>Kineret Subcutaneous Solution Prefilled Syringe</b> .....	8	
<b>Kisqali (200 MG Dose)</b> .....	112	
<b>Kisqali (400 MG Dose)</b> .....	112	
<b>Kisqali (600 MG Dose)</b> .....	112	
<b>Kisqali 200 Dose</b> .....	112	
<b>Kisqali 400 Dose</b> .....	112	
<b>Kisqali 600 Dose</b> .....	112	
<b>Kisqali Femara (200 MG Dose)</b> .....	112	
<b>Kisqali Femara (400 MG Dose)</b> .....	112	
<b>Kisqali Femara (600 MG Dose)</b> .....	112	
<b>Kynamro Subcutaneous Solution Prefilled Syringe</b> .....	78	
Lacosamide Oral Solution 10 MG/ML.....	68	
<b>Lagevrio</b> .....	80	
Lanthanum Carbonate.....	70	
Lapatinib Ditosylate.....	71	
Lenalidomide.....	72	
<b>Lenvima (10 MG Daily Dose)</b> .....	73	
<b>Lenvima (12 MG Daily Dose)</b> .....	73	
<b>Lenvima (14 MG Daily Dose)</b> .....	73	
<b>Lenvima (18 MG Daily Dose)</b> .....	73	
<b>Lenvima (20 MG Daily Dose)</b> .....	73	
<b>Lenvima (24 MG Daily Dose)</b> .....	73	
<b>Lenvima (4 MG Daily Dose)</b> .....	73	
<b>Lenvima (8 MG Daily Dose)</b> .....	73	
Liraglutide.....	74	
<b>Lokelma</b> .....	124	
<b>Lonsurf</b> .....	137	
<b>Lynparza Oral Tablet</b> .....	89	
<b>Mavyret Oral Tablet</b> .....	55	
<b>Mekinist Oral Tablet</b> .....	139	
<b>Menest Oral Tablet 0.3 MG, 0.625 MG, 1.25 MG</b> .....	45	
Mirabegron ER.....	79	
<b>Movantik</b> .....	82	
<b>Multaq</b> .....	34	
<b>Nerlynx</b> .....	83	
<b>Neupro</b> .....	116	
<b>Nicotrol</b> .....	84	
<b>Ninlaro</b> .....	67	
<b>Noxafil Oral Suspension</b> .....	108	
<b>Nubeqa</b> .....	26	

<b>Nucala</b> .....	76	<b>Retacrit Injection Solution</b>		<b>Xalkori Oral Capsule</b> .....	23
<b>Nuedexta</b> .....	31	<b>10000 UNIT/ML, 2000</b>		<b>Xeljanz Oral Solution</b> .....	138
<b>Ocrevus</b> .....	87	<b>UNIT/ML, 20000 UNIT/ML,</b>		<b>Xeljanz Oral Tablet</b> .....	138
<b>Odomzo</b> .....	126	<b>3000 UNIT/ML, 4000 UNIT/ML,</b>		<b>Xeljanz XR</b> .....	138
<b>Omnipod 5 DexG7G6 Intro Gen</b>		<b>40000 UNIT/ML</b> .....	41	<b>Xeomin</b> .....	61
<b>5</b> .....	91	<b>risperiDONE Microspheres ER..</b>	115	<b>Xifaxan</b> .....	113
<b>Omnipod 5 DexG7G6 Pods Gen</b>		<b>Rozlytrek Oral Capsule</b> .....	39	<b>Xolair</b> .....	90
<b>5</b> .....	91	<b>Rufinamide</b> .....	117	<b>Xtandi</b> .....	40
<b>Omnipod 5 G7 Intro (Gen 5)</b> .....	91	<b>Rydapt</b> .....	77	<b>Yesintek Subcutaneous</b> .....	142
<b>Omnipod 5 G7 Pods (Gen 5)</b> .....	91	<b>Sildenafil Citrate Oral Tablet 20</b>		<b>Zejula Oral Capsule</b> .....	86
<b>Omnipod Classic Pods (Gen 3)</b> .....	91	<b>MG</b> .....	121	<b>Zelboraf</b> .....	144
<b>Omnipod DASH Pods (Gen 4)</b> .....	91	<b>Sodium Oxybate</b> .....	123	<b>Zepatier</b> .....	55
<b>Omnitrope Subcutaneous</b>		<b>Somatuline Depot</b> .....	69	<b>Zileuton ER</b> .....	151
<b>Solution Cartridge</b> .....	125	<b>SORAfenib Tosylate</b> .....	127	<b>Zolanza</b> .....	148
<b>Omnitrope Subcutaneous</b>		<b>Stivarga</b> .....	111	<b>Zydelig</b> .....	59
<b>Solution Reconstituted</b> .....	125	<b>Stremsiq</b> .....	12	<b>Zykadia Oral Tablet</b> .....	19
<b>Oriahnn</b> .....	36	<b>SUNItinib Malate</b> .....	128	<b>Zyprexa Relprevv</b> .....	88
<b>Orilissa</b> .....	35	<b>Sunosi Oral Tablet 150 MG, 75</b>			
<b>Oxandrolone Oral</b> .....	94	<b>MG</b> .....	129		
<b>Panretin</b> .....	6	<b>Sylatron Subcutaneous Kit 200</b>			
<b>PAZOPanib HCl</b> .....	99	<b>MCG, 300 MCG, 600 MCG</b> .....	101		
<b>Penicillamine Oral Capsule</b> .....	102	<b>SymlinPen 120 Subcutaneous</b>			
<b>Pentamidine Isethionate</b>		<b>Solution Pen-Injector</b> .....	109		
<b>Inhalation</b> .....	103	<b>SymlinPen 60 Subcutaneous</b>			
<b>Pirfenidone</b> .....	105	<b>Solution Pen-Injector</b> .....	109		
<b>Pomalyst</b> .....	106	<b>Synarel</b> .....	81		
<b>Posaconazole Oral Tablet</b>		<b>Tadalafil (PAH)</b> .....	130		
<b>Delayed Release</b> .....	108	<b>Tafinlar Oral Capsule</b> .....	24		
<b>Prolia Subcutaneous Solution</b>		<b>Tagrisso</b> .....	93		
<b>Prefilled Syringe</b> .....	30	<b>Tasigna</b> .....	85		
<b>Promacta Oral Packet 12.5 MG</b> .....	37	<b>Tazarotene External Cream</b> .....	131		
<b>Promacta Oral Tablet</b> .....	37	<b>Tazarotene External Gel</b> .....	131		
<b>Pulmozyme Inhalation Solution</b>		<b>Teriflunomide</b> .....	132		
<b>2.5 MG/2.5ML</b> .....	33	<b>Teriparatide Subcutaneous</b>			
<b>Pyrimethamine Oral</b> .....	110	<b>Solution Pen-Injector 620</b>			
<b>Rebif Rebidose Subcutaneous</b>		<b>MCG/2.48ML</b> .....	133		
<b>Solution Auto-Injector</b> .....	63	<b>Tetrabenazine</b> .....	134		
<b>Rebif Rebidose Titration Pack</b>		<b>Thalomid</b> .....	136		
<b>Subcutaneous Solution Auto-</b>		<b>Tretinoin External Cream</b> .....	141		
<b>Injector</b> .....	63	<b>Tretinoin External Gel 0.01 %, 0.025 %</b> .....	141		
<b>Rebif Subcutaneous Solution</b>		<b>Tretinoin Oral</b> .....	140		
<b>Prefilled Syringe</b> .....	63	<b>Trintellix</b> .....	149		
<b>Rebif Titration Pack</b>		<b>Udenyca</b> .....	100		
<b>Subcutaneous Solution</b>		<b>Udenyca Onbody</b> .....	100		
<b>Prefilled Syringe</b> .....	63	<b>Venclexta</b> .....	145		
		<b>Venclexta Starting Pack</b> .....	145		
		<b>Verzenio</b> .....	1		
		<b>Voriconazole Oral</b> .....	147		